Galapagos and BASF extend research collaborations

2/2/2006, 8:00 AM (Source: GlobeNewswire)
Mechelen, Belgium; 2 February, 2006 - Galapagos NV (Euronext & LSE: GLPG) announced today that it has extended three research collaborations into 2006 with BASF Aktiengesellschaft (NYSE & XET: BASF) in Ludwigshafen, Germany. These extensions will further progress discovery research services for BASF programmes successfully undertaken by Galapagos' service division BioFocus in 2005. Across the various programmes, BioFocus will offer biology, synthetic and computational chemistry services, plus access to its biologically-targeted SoftFocus® Kinase and GPCR compound libraries against further BASF targets. Under the terms of the extension agreements, BASF will pay compound supply and access fees and will fund research activities. Total contract value of the extensions announced today will exceed € 700,000.

"We are delighted that BASF has chosen to extend these collaborations
with BioFocus," said Onno van de Stolpe, CEO of Galapagos. "We
believe that our expertise in the area of kinase and GPCR biology and
chemistry, together with our proprietary compound libraries, place
BioFocus in an excellent position to progress BASF's discovery
programmes rapidly."

About Galapagos

Galapagos is a publicly traded, genomics-based drug discovery company
(Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA, London AiM:
GLPG) that has drug discovery programs based on proprietary, novel
targets in the bone and joint diseases - osteoarthritis, osteoporosis
and rheumatoid arthritis. Galapagos offers a full suite of
target-to-drug discovery products and services to pharmaceutical and
biotech companies through its division BioFocus, encompassing target
discovery and validation, and drug discovery services through to
delivery of pre-clinical candidates. In addition, BioFocus provides
adenoviral reagents for rapid identification and validation of novel
drug targets and compound libraries for screening. Galapagos
currently employs 203 people, including 76 PhDs, and occupies
facilities in Mechelen, Belgium, Saffron Walden, UK and Leiden, The
Netherlands. The partners of Galapagos include Amgen, AstraZeneca,
Bayer, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Idenix,
Novartis, Organon, Serono, Vertex, and Wyeth. More information about
Galapagos and BioFocus can be found at www.glpg.com.
CONTACT

Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.